



New Molecular Entities for 2003


ABARELIX
Plenaxis™




ALFUZOSIN
UroXatral™




APREPITANT



ATAZANAVIR
Reyataz™




BORTEZOMIB
Velcade™



DAPTOMYCIN


Cubicin™



Polypeptide antibiotic
Approved Sept

DERACOXIB


Deramax™




Canine COX2 inhibitors
Approved April

ENFUVRITIDE


Fuzeon™




Anti HIV, fusion inhibitor
Approved March




5-HT₁ agonist for migraine
Approved January




anti HIV-1 reverse transcriptase
Approved July.




H₁ antagonist,
mast cell stabilizer
Approved Oct




protease inhibitor for HIV
Approved Oct




for cancer-related
hypercalcemia




epidermal growth factor receptor inhibitor
in lung cancer
Approved May




Quinolone
Approved April




Bisphosphonate
Approved June




NMDA antagonist for Alzheimer's
Approved Oct



Glucosylceramide synthase inhibitor
for Gaucher disease




5-HT₃ antagonist in
chemotherapy induced N & V
Approved July




prevent absorption of Cs or Tl
Approved October

ROSUVASTATIN calcium
Crestor™



SERTACONAZOLE


Ertaczo



Imidazole antifungal
Approved December

HMG-CoA reductase inhibitor
Approved August


TADALAFIL
Cialis™



treat erectile dysfunction in men
Approved November

VARDENAFIL

Levitra™



treat erectile dysfunction in men
Approved August